Barricaid Annular Closure Device
Prevention of reherniation following lumbar discectomy in patients with large annular defects
ApprovedActive
Key Facts
Indication
Prevention of reherniation following lumbar discectomy in patients with large annular defects
Phase
Approved
Status
Active
Company
About Intrinsic Therapeutics
Intrinsic Therapeutics is a commercial-stage medical device company that has developed and markets the Barricaid annular closure device. The device is clinically proven to reduce reherniation and subsequent reoperation rates in lumbar discectomy patients with large annular defects, addressing a significant unmet need in spine surgery. With over two decades of development and a strong body of published clinical evidence, including Level 1 RCT data, the company is focused on driving surgeon adoption and patient access. Its business model centers on the sale of the implantable device to hospitals and surgical centers.
View full company profile